The role of epigenetic mechanisms in the pathogenesis of diabetic nephropathy
https://doi.org/10.36485/1561-6274-2021-25-2-35-42
Abstract
Diabetic nephropathy (DN) is a chronic complication of diabetes and the most common cause of the end-stage renal disease (ESRD). Numerous factors have been considered, both contributing to the development of DN, and participating in its pathogenesis. However, to date, the molecular mechanisms, that lead to the development of DN, remain not fully understood. Recently, with the development of high-performance technologies, evidence demonstrating epigenetic mechanisms of regulation of gene expression, including DNA methylation, non-coding RNAs, and histone modifications that play a key role in the pathogenesis of DN through the secondary regulation of genes are starting to appear. All these data can contribute to the creation of new, more effective diagnostic and therapeutic technologies for DN.
About the Authors
K. A. Aitbaev
Research Institute of Molecular Biology and Medicine
Kyrgyzstan
Kyrgyzstan
Kubanych A. Aitbaev, MD, PhD, DMedSci; Head of the Department of Pathological Physiology; Member of the Board of the Society of Chronic Kidney Disease Specialists
720040, Kyrgyzstan, Bishkek, T. Moldo, Street, 3
Phone: (312) 66-25-13
I. T. Murkamilov
I.K.Akhunbaev Kyrgyz State Medical Academy
Kyrgyzstan
Kyrgyzstan
Ilkhom T. Murkamilov, MD, PhD; acting associate professor of the Department of faculty therapy; Senior lecturer; Chairman of the board of Chronic Kidney Disease specialists
720020, Kyrgyzstan, Bishkek, Akhunbaev Street, 92
Phone: (312) 62-09-91
V V Fomin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Сorresponding member of RAS Viktor V. Fomin, MD, PhD, DMedSci; Head of the Department of Faculty Therapy No.1
119146, Russia, Moscow, 6 Bolshaya Pirogovskaya, Street 6
Phone: +7 (499) 248-62-22
Zh. A. Murkamilova
Kyrgyz Russian Slavic University
Kyrgyzstan
Kyrgyzstan
Correspondence graduate student Zhamila A. Murkamilova, MD; Department of Therapy No. 2
720000, Kyrgyzstan, Bishkek, Kiev, Street, 44
Phone: (+996) 552435009
F. A. Yusupov
Osh State University
Kyrgyzstan
Kyrgyzstan
Furkat A. Yusupov, MD, PhD; Head of the Department of neurology, psychiatry and medicinal genetics of medicinal
faculty; Board member of Chronic Kidney Disease specialists
714000, Kyrgyzstan, Osh, Lenin Street, 331
Phone: (+996) 557202071
References
1. Shestakova MV, Shamkhalova MS, Yarek-Martynova IY et al. Diabetes mellitus and chronic kidney disease: achievements, unresolved problems, and prospects for therapy. Diabetes mellitus 2011;14:1:81-88
2. Kamyshova ES, Bobkova IN, Kutyrina IM. New insights on microRNAs in diabetic nephropathy: potential biomarkers for diagnosis and therapeutic targets. Diabetes mellitus 2017;20:1:42-50. https://doi.org/10.14341/DM8237
3. Regele F, Jelencsics K, Shiffman D et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrology Dialysis Transplantation 2015; 30 (4): iv26–iv34. https://doi.org/10.1093/ndt/gfv087
4. Cowie CC, Port FK, Wolfe RA et al. Disparities in incidence of diabetic endstage renal disease according to race and type of diabetes. New England Journal of Medicine 1989; 321(16):1074–1079. https://doi.org/10.1056/NEJM198910193211603
5. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nature Reviews Endocrinology 2010; 6(12):665–675. https://doi.org/10.1038/nrendo.2010.188
6. Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnology 2010; 28 (10):1057–1068. https:// doi.org/10.1038/nbt.1685
7. Thomas MC. Epigenetic mechanisms in diabetic kidney disease. Current Diabetes Reports 2016;16:3:31. https://doi.org/10.1007/s11892-016-0723-9
8. Jones PA. Functions of DNA methylation: islands, startsites, gene bodies and beyond. Nature Reviews Genetics 2012; 13 (7):484–492. https://doi.org/10.1038/nrg3230
9. Barres R, Osler ME, Yan J et al. Non-CpG methylation of the PGC-1α promoter through DNMT3B controls mitochondrial density. Cell Metabolism 2009; 10(3):189–198. https://doi.org/10.1016/j.cmet.2009.07.011
10. Marumo T, Yagi S, Kawarazaki W et al. Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney. Journal of the American Society of Nephrology 2015; 26 (10):2388–2397. https://doi.org/10.1681/ASN.2014070665
11. Wu R, Wang L, Yin R, et al. Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatorydriven colon cancer. Molecular Carcinogenesis 2020. https://doi.org/10.1002/mc.23146
12. Gu HF. Genetic and epigenetic studies in diabetic kidney disease. Frontiers in genetics 2019;10:507. https://doi.org/10.3389/fgene.2019.00507
13. Bell CG, Teschendorff AE, Rakyan VK et al. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Medical Genomics 2010;3:33. https://doi.org/10.1186/1755-8794-3-33
14. Sapienza C, Lee J, Powell J et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011; 6(1):20–28. https://doi.org/10.4161/epi.6.1.13362
15. Hasegawa K, Wakino S, Simic P et al. Renal tubular sirt1 attenuates diabetic albuminuria by epigenetically suppressing claudin-1 overexpression in podocytes. Nature Medicine 2013; 19(11):1496–1504. https://doi.org/10.1038/nm.3363
16. Ko Y-A, Mohtat D, Suzuki M et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biology 2013;14(10): article R108. https://doi.org/10.1186/gb-2013-14-10-r108
17. Bechtel W, McGoohan S, Zeisbergetal EM. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nature Medicine 2010;5:16:544–550. https://doi.org/10.1038/nm.2135
18. Pirola L, Balcerczyk A, Tothill RW et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Research 2011; 21(10):1601–1615. https://doi.org/10.1101/gr.116095.110
19. Liang F, Holt I, Pertea G et al. Gene index analysis of the human genome estimates approximately 120,000 genes. Nature Genetics 2000; 25(2): 239–240. https://doi.org/10.1038/76126
20. Kapranov P, Cawley SE, Drenkow J et al. Large-scale transcriptional activity in chromosomes 21 and 22. Science 2002; 296 (5569):916–919. Doi: 10.1126/science.1068597
21. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 2012;489:101–108. https://doi.org/10.1038/nature11233
22. Consortium Encode Project. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57–74. https://doi.org/10.1038/nature11247
23. Okazaki Y, Furuno M, Kasukawa T et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002; 420: 563–573. https://doi.org/10.1038/nature01266
24. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136 (2):215–233. https://doi.org/10.1016/j.cell.2009.01.002
25. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research 2014;1:42:D68–D73. https://doi.org/10.1093/nar/gkt1181
26. Sun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic acids research 2004; 32(22): article e188. https://doi.org/10.1093/nar/gnh186
27. Tian Z, Greene AS, Pietrusz JL et al. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Research 2008; 18(3):404–411. https://doi.org/10.1101/gr.6587008
28. Wu H, Kong L, Zhou S et al. The role of microRNAs in diabetic nephropathy. Journal of Diabetes Research 2014; 2014: article ID 920134, 12 pages. https://doi.org/10.1155/2014/920134
29. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences of the United States of America 2007;104(9):3432–3437. https://doi.org/10.1073/pnas.0611192104
30. Chung ACK, Huang XR, Meng X, Lan XY. miR-192 mediates TGF-β/Smad3-driven renal fibrosis. Journal of the American Society of Nephrology 2010; 21(8):1317–1325. https://doi.org/10.1681/ASN.2010020134
31. Krupa A, Jenkins R, DongLuo D et al. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. Journal of the American Society of Nephrology 2010; 21(3):438–447. https://doi.org/10.1681/ASN.2009050530
32. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-β. Diabetes 2010;59(7):1794–1802. https://doi.org/10.2337/db09-1736
33. Kato M, Natarajan R. Diabetic nephropathy-emerging epigenetic mechanisms. Nature Reviews Nephrology 2014;10 (9):517–530. https://doi.org/10.1038/nrneph.2014.116
34. Deshpande SD, Putta S, Wang M et al. Transforming growth factor-β-induced cross talk between p53 and a MicroRNA in the pathogenesis of diabetic nephropathy. Diabetes 2013; 62(9):3151–3162. https://doi.org/10.2337/db13-0305
35. Kato M, Natarajan R. MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets. Annals of the New York Academy of Sciences 2015; 1353:72–88. https://doi.org/10.1111/nyas.12758
36. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology 2012; 23(3):458–469. https://doi.org/10.1681/ASN.2011050485
37. Jia Y, Guan M, Zheng Z et al. MiRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. Journal of Diabetes Research 2016; 2016: Article ID 7932765, 10 pages. https://doi.org/10.1155/2016/7932765
38. Kato M, Arce L, Wang M et al. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney International 2011; 80(4): 358–368. https://doi.org/10.1038/ki.2011.43
39. Zhong X, Chung ACK, Chen HY et al. MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56(3):663–674. https://doi.org/10.1007/s00125-012-2804-x
40. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annual Review of Biochemistry 2012; 81: 145–166. https://doi.org/10.1146/annurev-biochem-051410-092902
41. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136 (4):629–641. https://doi.org/10.1016/j.cell.2009.02.006
42. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Current Biology 2010; 20 (19):R858–R861. https://doi.org/10.1016/j.cub.2010.08.052
43. Yang X, Tao L, Zhu J, Zhang S. Long Noncoding RNA FTX Reduces Hypertrophy of Neonatal Mouse Cardiac Myocytes and Regulates the PTEN/PI3K/Akt Signaling Pathway by Sponging MicroRNA-22. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2019;25:9609-9617. https://doi.org/10.12659/MSM.919654
44. Reichelt-Wurm S, Wirtz T, Chittka D, et al. Glomerular expression pattern of long non-coding RNAs in the type 2 diabetes mellitus BTBR mouse model. Scientific reports 2019;9:1:1-13. https://doi.org/10.1038/s41598-019-46180-1 45. Kato M, Putta S, Wang M et al. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nature Cell Biology 2009;11(7):881–889. https://doi.org/10.1038/ncb1897
45. Kato M, Dang V, Wang M et al. TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Science Signaling 2013;6 (278): article no. ra43. https://doi.org/10.1126/scisignal.2003389
46. Kato M, Wang M, Chen Z et al. An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. Nature Communications 2016;7: article 12864. https://doi.org/10.1038/ncomms12864
47. Zhou Q, Chung ACK, Huang XR, Dong Y, Yu X, Lan HY. Identification of novel long noncoding rnas associated with TGF-β/ Smad3-mediated renal inflammation and fibrosis by RNA sequencing. American Journal of Pathology 2014;184(2):409-417. https:// doi.org/10.1016/j.ajpath.2013.10.007
48. Long J, Badal SS, Ye Z et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. Journal of Clinical Investigation 2016;126(11):4205–4218. https:// doi.org/10.1172/JCI87927
49. Ji P, Diederichs S, Wang W et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003;22 (39):8031–8041. https://doi.org/10.1038/sj.onc.1206928
50. Liu J.-Y, Yao J, Li X.-M et al. Pathogenic role of lncRNA MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death and Disease 2014; 5: article ID e1506. https://doi.org/10.1038/cddis.2014.466
51. Puthanveetil P, Chen S, Feng B, Gautam A, Chakrabarti S. Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. Journal of Cellular and Molecular Medicine 2015; 19 (6):1418–1425. https://doi.org/10.1111/jcmm.12576
52. Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4):693–705. https://doi.org/10.1016/j.cell.2007.02.005
53. Liu R, Lee K, He JC. Genetics and epigenetics of diabetic nephropathy. Kidney Diseases 2015; 1(1):42–51. https:// doi.org/10.1159/000381796
54. El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine 2008; 205:2409–2417. https://doi.org/10.1084/jem.20081188 56. Sun G, Reddy MA,Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. Journal of the American Society of Nephrology 2010; 21 (12):2069–2080. https://doi.org/10.1681/ASN.2010060633
55. Bock F, Shahzad K, Wang H et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proceedings of the National Academy of Sciences of the United States of America 2013; 110 (2): 648–653. https://doi.org/10.1073/pnas.1218667110
56. Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetology & metabolic syndrome 2019;11:1:7. https://doi.org/10.1186/s13098-019-0403-4
57. Raval N, Kumawat A, Kalyane D, Kalia K, Tekade RK. Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities. Drug Discovery Today 2020. https://doi.org/10.1016/j.drudis.2020.01.008
58. Li M, Guo Q, Cai H et al. miR-218 regulates diabetic nephropathy via targeting IKK-β and modulating NK-κB-mediated inflammation. Journal of cellular physiology 2020;235:4:3362-3371. https://doi.org/10.1002/jcp.29224
59. Nascimento LR, Domingueti CP. MicroRNAs: new biomarkers and promising therapeutic targets for diabetic kidney disease. Brazilian Journal of Nephrology 2019. AHEAD. http:// dx.doi.org/10.1590/2175-8239-jbn-2018-0165
60. Lai JY, Luo J, O’Connor C et al. MicroRNA-21 in glomerular injury. Journal of the American Society of Nephrology 2015;26 (4):805–816. DOI: https://doi.org/10.1681/ASN.2013121274
61. Mohan A, Singh RS, Kumari M et al. Urinary exosomal microRNA-451-5p is a potential early biomarker of diabetic nephropathy in rats. PLoS ONE 2016;11(4):article ID e0154055. https:// doi.org/10.1371/journal.pone.0154055
62. Dounousi E, Duni A, Leivaditis K et al. Improvements in the management of diabetic nephropathy. Review of Diabetic Studies 2015;12(1-2):119–133. https://doi.org/10.1900/RDS.2015.12.119
63. Tonna S, El-Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology 2010;6(6):332–341. https://doi.org/10.1038/nrneph.2010.55
Review
For citations:
Aitbaev K.A., Murkamilov I.T., Fomin V.V., Murkamilova Zh.A., Yusupov F.A. The role of epigenetic mechanisms in the pathogenesis of diabetic nephropathy. Nephrology (Saint-Petersburg). 2021;25(2):35-42. (In Russ.) https://doi.org/10.36485/1561-6274-2021-25-2-35-42
Views:
822
Email this article 